Equillium (EQ)
(Delayed Data from NSDQ)
$1.79 USD
+0.07 (4.07%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $1.76 -0.03 (-1.68%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EQ 1.79 +0.07(4.07%)
Will EQ be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EQ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EQ
5 Stocks That More Than Doubled in Q1 With More Gains Ahead
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
EQ: What are Zacks experts saying now?
Zacks Private Portfolio Services
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark
Other News for EQ
Short interest on energy stocks up in March; APA and EQT most shorted, COP least shorted
EQ Inc. Celebrates a Profitable, Growth-Fueled Quarter
EQ Inc. Reports Profitable Fourth Quarter and 2023 Year End Financial Results
Buy Rating Affirmed for Equillium on Strong Clinical Data and Potential Financial Upsides
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)